title: C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s.
authors.affiliation: HIV Program Hennepin County Medical Center, University of Minnesota, Minneapolis, MN, USA.
authors.forename: Keith
authors.initials: K
authors.lastname: Henry
authors.forename: Douglas
authors.initials: D
authors.lastname: Kitch
authors.forename: Michael
authors.initials: M
authors.lastname: Dube
authors.forename: Robert
authors.initials: R
authors.lastname: Zackin
authors.forename: Robert A
authors.initials: RA
authors.lastname: Parker
authors.forename: Dennis
authors.initials: D
authors.lastname: Sprecher
authors.forename: Scott
authors.initials: S
authors.lastname: Hammer
authors.forename: Judith
authors.initials: J
authors.lastname: Currier
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002097:C-Reactive Protein / Q000378:metabolism*; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000139:chemically induced*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000009:adverse effects*; D008297:Male; D012307:Risk Factors
chemical_list: D017320:HIV Protease Inhibitors; D019469:Indinavir; D002097:C-Reactive Protein